FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078021975> ?p ?o ?g. }

• W2078021975 endingPage "1308" @default.
• W2078021975 startingPage "1302" @default.
• W2078021975 abstract "The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure states. DR15 has also been associated with favorable outcomes (reduced acute graft-versus-host disease [aGVHD] and relapse) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem cell transplant from HLA-matched sibling donors for the treatment of acute leukemia, chronic myeloid leukemia, or myelodysplastic syndrome (MDS) between 1990 and 2007. All patients received conventional myeloablative conditioning, T-replete grafts, and cyclosporine plus methotrexate-based GVHD prophylaxis. DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%) as negative for DRB1*15:01 or *15:02 (DR15). There were no significant differences in baseline characteristics between the HLA DR15 positive and negative groups. In univariate analysis, HLA-DR15 status had no impact on neutrophil engraftment, aGVHD, chronic GVHD (cGVHD), treatment-related mortality, relapse, disease-free survival, or overall survival (OS). In multivariate analysis, DR15 status showed no significant difference in aGVHD, cGVHD, OS, or relapse. In conclusion, DR15 status had no impact on major HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort of patients with leukemia and MDS. The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure states. DR15 has also been associated with favorable outcomes (reduced acute graft-versus-host disease [aGVHD] and relapse) after allogeneic hematopoietic cell transplant. To elucidate the impact of DR15 on transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem cell transplant from HLA-matched sibling donors for the treatment of acute leukemia, chronic myeloid leukemia, or myelodysplastic syndrome (MDS) between 1990 and 2007. All patients received conventional myeloablative conditioning, T-replete grafts, and cyclosporine plus methotrexate-based GVHD prophylaxis. DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%) as negative for DRB1*15:01 or *15:02 (DR15). There were no significant differences in baseline characteristics between the HLA DR15 positive and negative groups. In univariate analysis, HLA-DR15 status had no impact on neutrophil engraftment, aGVHD, chronic GVHD (cGVHD), treatment-related mortality, relapse, disease-free survival, or overall survival (OS). In multivariate analysis, DR15 status showed no significant difference in aGVHD, cGVHD, OS, or relapse. In conclusion, DR15 status had no impact on major HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort of patients with leukemia and MDS." @default.
• W2078021975 created "2016-06-24" @default.
• W2078021975 creator A5001697191 @default.
• W2078021975 creator A5005657988 @default.
• W2078021975 creator A5012535366 @default.
• W2078021975 creator A5016644532 @default.
• W2078021975 creator A5029278364 @default.
• W2078021975 creator A5031293676 @default.
• W2078021975 creator A5040185213 @default.
• W2078021975 creator A5041976525 @default.
• W2078021975 creator A5043914134 @default.
• W2078021975 creator A5054714265 @default.
• W2078021975 creator A5058557833 @default.
• W2078021975 creator A5058862489 @default.
• W2078021975 creator A5064818358 @default.
• W2078021975 creator A5065897197 @default.
• W2078021975 creator A5073620732 @default.
• W2078021975 creator A5074515375 @default.
• W2078021975 creator A5076881385 @default.
• W2078021975 creator A5082092102 @default.
• W2078021975 creator A5083504452 @default.
• W2078021975 creator A5085360755 @default.
• W2078021975 creator A5088647781 @default.
• W2078021975 creator A5088800804 @default.
• W2078021975 creator A5088962035 @default.
• W2078021975 date "2012-08-01" @default.
• W2078021975 modified "2023-10-18" @default.
• W2078021975 title "HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies" @default.
• W2078021975 cites W1530764705 @default.
• W2078021975 cites W1535095237 @default.
• W2078021975 cites W1966766916 @default.
• W2078021975 cites W1978350548 @default.
• W2078021975 cites W1979302706 @default.
• W2078021975 cites W1993013407 @default.
• W2078021975 cites W2001589632 @default.
• W2078021975 cites W2014958310 @default.
• W2078021975 cites W2023363318 @default.
• W2078021975 cites W2033292292 @default.
• W2078021975 cites W2033654955 @default.
• W2078021975 cites W2039808932 @default.
• W2078021975 cites W2123513217 @default.
• W2078021975 cites W2126252211 @default.
• W2078021975 cites W2132101695 @default.
• W2078021975 cites W2159722655 @default.
• W2078021975 cites W2245154954 @default.
• W2078021975 cites W2262764660 @default.
• W2078021975 cites W2979658253 @default.
• W2078021975 cites W4231722547 @default.
• W2078021975 cites W4293241248 @default.
• W2078021975 cites W830428549 @default.
• W2078021975 doi "https://doi.org/10.1016/j.bbmt.2012.02.011" @default.
• W2078021975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3580851" @default.
• W2078021975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22414493" @default.
• W2078021975 hasPublicationYear "2012" @default.
• W2078021975 type Work @default.
• W2078021975 sameAs 2078021975 @default.
• W2078021975 citedByCount "10" @default.
• W2078021975 countsByYear W20780219752013 @default.
• W2078021975 countsByYear W20780219752014 @default.
• W2078021975 countsByYear W20780219752016 @default.
• W2078021975 countsByYear W20780219752017 @default.
• W2078021975 countsByYear W20780219752018 @default.
• W2078021975 countsByYear W20780219752020 @default.
• W2078021975 countsByYear W20780219752022 @default.
• W2078021975 countsByYear W20780219752023 @default.
• W2078021975 crossrefType "journal-article" @default.
• W2078021975 hasAuthorship W2078021975A5001697191 @default.
• W2078021975 hasAuthorship W2078021975A5005657988 @default.
• W2078021975 hasAuthorship W2078021975A5012535366 @default.
• W2078021975 hasAuthorship W2078021975A5016644532 @default.
• W2078021975 hasAuthorship W2078021975A5029278364 @default.
• W2078021975 hasAuthorship W2078021975A5031293676 @default.
• W2078021975 hasAuthorship W2078021975A5040185213 @default.
• W2078021975 hasAuthorship W2078021975A5041976525 @default.
• W2078021975 hasAuthorship W2078021975A5043914134 @default.
• W2078021975 hasAuthorship W2078021975A5054714265 @default.
• W2078021975 hasAuthorship W2078021975A5058557833 @default.
• W2078021975 hasAuthorship W2078021975A5058862489 @default.
• W2078021975 hasAuthorship W2078021975A5064818358 @default.
• W2078021975 hasAuthorship W2078021975A5065897197 @default.
• W2078021975 hasAuthorship W2078021975A5073620732 @default.
• W2078021975 hasAuthorship W2078021975A5074515375 @default.
• W2078021975 hasAuthorship W2078021975A5076881385 @default.
• W2078021975 hasAuthorship W2078021975A5082092102 @default.
• W2078021975 hasAuthorship W2078021975A5083504452 @default.
• W2078021975 hasAuthorship W2078021975A5085360755 @default.
• W2078021975 hasAuthorship W2078021975A5088647781 @default.
• W2078021975 hasAuthorship W2078021975A5088800804 @default.
• W2078021975 hasAuthorship W2078021975A5088962035 @default.
• W2078021975 hasBestOaLocation W20780219751 @default.
• W2078021975 hasConcept C126322002 @default.
• W2078021975 hasConcept C143998085 @default.
• W2078021975 hasConcept C147483822 @default.
• W2078021975 hasConcept C188280979 @default.
• W2078021975 hasConcept C202965653 @default.
• W2078021975 hasConcept C203014093 @default.
• W2078021975 hasConcept C2777408962 @default.
• W2078021975 hasConcept C2778461978 @default.

• next